STOCKHOLM, Sept. 17, 2021 /PRNewswire/ -- NeoDynamics has
received orders from four high profile clinics in Germany and Switzerland for its novel biopsy system
NeoNavia. This positive development shows that clinics are
advancing to the next level in evaluating the system and
progressing towards incorporating it into their clinical
practice.
"I am delighted that the launch of NeoNavia is progressing well
despite the limitations the pandemic continues to place on our
introduction of the system to clinics in the German speaking part
of Europe. Physicians appreciate
how easy the system is to handle and are enthusiastic about the
size of the tissue samples they receive as well as the ability to
take samples from areas that are hard to reach," says Country
Manager Renate Reiss.
"The feedback we are receiving from clinics evaluating NeoNavia
is positive, and I expect this to continue as restrictions lift and
the clinical experience with NeoNavia grows," says CEO Anna Eriksrud.
The system consists of a base unit, a handheld driver and three
different types of biopsy needles, also called probes. The orders,
which are for probes, will be delivered to clinics in Germany and Switzerland mainly in the fourth quarter 2021.
Orders for probes are expected to be placed on a recurring basis
once the system has been incorporated in the practice at a
clinic.
For further information, please contact:
Anna Eriksrud, CEO NeoDynamics
AB, phone +46 708 444 966 or e-mail
anna.eriksrud@neodynamics.
About NeoDynamics
NeoDynamics AB (publ) is a Swedish Medical Technology Company
dedicated to advancing diagnosis and care of breast cancer. The
company's first product NeoNavia®, a new innovative pulse biopsy
system for ultrasound guided tissue sampling, is currently being
introduced to the market. The biopsy system is built on a patented
pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast
cancer diagnosis at leading clinics in UK, Germany, and Sweden. The pulse biopsy system has been used
for tissue sampling in breast and axilla in over 500 patients.
About NeoNavia
NeoNavia is a modern biopsy system with a completely new
patented pulse technology intended for ultrasound-guided tissue
sampling. It consists of a base unit, a handheld driver and three
different types of biopsy needles. Each needle type is driven by
the pulse technology providing a more controlled needle insertion
and precise placement of the needle in the tumour whilst enabling
high-quality tissue samples from both breasts and lymph nodes. The
pulse biopsy system NeoNavia is designed to offer clinicians and
patients accurate lesion targeting and high tissue yield for
correct diagnosis and individualized treatment.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/neodynamics/r/neodynamics-confirms-four-orders-for-neonavia,c3416767
The following files are available for download:
https://mb.cision.com/Main/17640/3416767/1469390.pdf
|
2109-NEOD PR
orders
|